Free Newsletter
Merck’s rotavirus vaccine makes big impact
A new report by the CDC concludes that Merck's new rotavirus vaccine has made a major impact on the disease in the last two years. RotaTeq, designed to prevent diarrhea and vomiting in children, has pushed the start of the rotavirus season back by three months and reduced the severity of the season by half. Incidences of the disease plunged soon after the vaccine was approved and swiftly hit their lowest level since figures were first gathered 15 years ago. Rotavirus is highly contagious and has been blamed for 272,000 ER visits in the U.S. each year.
- read the report in the Philadelphia Inquirer
Related Articles:
FDA approves Merck's rotavirus vaccine
Vaccine may be linked to bowel problems in children
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment